SynCardia Systems (Tucson, Arizona), a developer of cardiac replacement and assist devices, in mid-October received final FDA approval for its CardioWest Temporary Total Artificial Heart (TAH-t) – formerly the CardioWest Total Artificial Heart – as a bridge to heart transplantation. Specifically, the approval is for use in cardiac transplant-eligible candidates at risk of imminent death from non-reversible biventricular failure.